Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Incannex HealthcareIXHL +3.80%32 Earnings per Share (Diluted) is $-6.43 as of Mar. 2026. GuruFocus rates IXHL with a GF Score™ of 32/100. The stock has 2 warning signs investors should review. Among 786 Drug Manufacturers companies, Incannex Healthcare ranks better than 84.73% on this metric.
Incannex Healthcare's EPS (Basic) for the
three
months ended in Mar. 2026 was $-0.35.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was $-6.43.
During the past 3 years, the average EPS without NRIGrowth Rate was 42.20% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was -48.80% per year.
During the past 10 years, the average EPS without NRIGrowth Rate was -79.20% per year.
During the past 13 years, Incannex Healthcare's highest 3-Year average EPS without NRI Growth Rate was 73.40% per year. The lowest was -485.90% per year. And the median was 8.30% per year.
Incannex Healthcare (NAS:IXHL) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Incannex Healthcare Earnings per Share (Diluted) Related Terms
Incannex Healthcare Earnings per Share (Diluted) Historical Data
* Premium members only.
The historical data trend for Incannex Healthcare's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Incannex Healthcare Earnings per Share (Diluted) Chart
IXHL vs ETST, SCYX, INIS: Earnings per Share (Diluted) Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Incannex Healthcare's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Incannex Healthcare PE Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Incannex Healthcare's PE Ratio distribution charts can be found below:
* The bar in red indicates where Incannex Healthcare's PE Ratio falls into.
Incannex Healthcare Earnings per Share (Diluted) Calculation
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
Incannex Healthcare's Earnings Per Share (Diluted) for the fiscal year that ended in Jun. 2025 is calculated as
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.43
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
What does a Earnings per Share (Diluted) of $-6.43 mean?
Incannex Healthcare (IXHL) has a Earnings per Share (Diluted) of $-6.43 as of Mar. 2026. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Incannex Healthcare and its competitors. According to the industry distribution chart, Incannex Healthcare ranks #120 out of 786 companies in the Drug Manufacturers industry, placing it in the top 15.3%.
Is Incannex Healthcare's Earnings per Share (Diluted) too high?
Incannex Healthcare's current Earnings per Share (Diluted) is $-6.43. Based on the distribution chart, Incannex Healthcare ranks #120 out of 786 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Incannex Healthcare has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Incannex Healthcare's Earnings per Share (Diluted) compare to ETST and SCYX?
According to the Drug Manufacturers industry distribution chart, Incannex Healthcare ranks #120 out of 786 companies for Earnings per Share (Diluted). This places Incannex Healthcare in the top 15% of its industry — outperforming the majority of peers. The industry median Earnings per Share (Diluted) is 9.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings per Share (Diluted) for a Drug Manufacturers company?
The median Earnings per Share (Diluted) among Drug Manufacturers companies is 9.60, based on 786 companies in the industry. Companies in the top quartile (top 25%) have a Earnings per Share (Diluted) significantly above this median, while those in the bottom quartile fall well below. However, Earnings per Share (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings per Share (Diluted) mean?
A high Earnings per Share (Diluted) can signal that a stock is expensive relative to its fundamentals. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Incannex Healthcare and its competitors. For the Drug Manufacturers industry, the median Earnings per Share (Diluted) is 9.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Incannex Healthcare's current Earnings per Share (Diluted) is $-6.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Incannex Healthcare stock overvalued right now?
Incannex Healthcare (IXHL) has a current Earnings per Share (Diluted) of $-6.43. The current Earnings per Share (Diluted) is $-6.43. Incannex Healthcare's overall GF Score™ is 32/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings per Share (Diluted) calculated?
Earnings per Share (Diluted) is calculated from a company's financial statements. For Incannex Healthcare (IXHL), the current Earnings per Share (Diluted) is $-6.43 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.
32GF Score
Get the complete analysis for IXHL
Earnings per Share (Diluted) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IXHL has been successfully added to your 
